High-yield production of a human monoclonal IgG by rhizosecretion in hydroponic tobacco cultures.
Ontology highlight
ABSTRACT: Rhizosecretion of recombinant pharmaceuticals from in vitro hydroponic transgenic plant cultures is a simple, low cost, reproducible and controllable production method. Here, we demonstrate the application and adaptation of this manufacturing platform to a human antivitronectin IgG1 monoclonal antibody (mAb) called M12. The rationale for specific growth medium additives was established by phenotypic analysis of root structure and by LC-ESI-MS/MS profiling of the total protein content profile of the hydroponic medium. Through a combination of optimization approaches, mAb yields in hydroponic medium reached 46 μg/mL in 1 week, the highest figure reported for a recombinant mAb in a plant secretion-based system to date. The rhizosecretome was determined to contain 104 proteins, with the mAb he
SUBMITTER: Madeira LM
PROVIDER: S-EPMC11388865 | biostudies-literature | 2016 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA